恩格列净独立于缓解糖毒性改善2型糖尿病患者β细胞功能:以胰岛素为对照的随机交叉研究
本研究为开放标签随机交叉试验,17例非胰岛素治疗的2型糖尿病患者接受5周恩格列净或NPH胰岛素治疗,血糖控制相当。结果显示恩格列净治疗期间β细胞葡萄糖敏感性和胰岛素敏感性均高于胰岛素治疗,处置指数改善,提示β细胞功能改善可能独立于糖毒性缓解。
要点
- 在血糖控制相当的情况下,恩格列净较胰岛素治疗显著提高β细胞葡萄糖敏感性。
- 恩格列净治疗期间胰岛素敏感性高于胰岛素治疗,处置指数改善。
- β细胞功能改善可能部分归因于较低胰岛素浓度带来的去抑制效应。
核心结论
- 在血糖控制相似的情况下,恩格列净治疗较胰岛素治疗提高胰岛素敏感性和β细胞功能,可能源于较低胰岛素浓度的去抑制效应。
研究设计与样本
- 开放标签随机交叉研究,17例非胰岛素治疗的2型糖尿病患者随机接受5周恩格列净或NPH胰岛素治疗,洗脱期3周后交叉。
- 关键入选标准包括年龄≥18岁、BMI≥28 kg/m²、糖尿病病程>3个月。
主要发现
- 血糖控制相当的情况下,胰岛素治疗期间胰岛素浓度高于恩格列净治疗期间。
- 恩格列净治疗期间β细胞葡萄糖敏感性(bGS)和胰岛素敏感性均高于胰岛素治疗期间。
- 恩格列净治疗期间处置指数(bGS×胰岛素敏感性)较胰岛素治疗改善。
临床怎么用
- 对于非胰岛素治疗的2型糖尿病患者,恩格列净在相似血糖控制下可能较胰岛素更有利于改善β细胞功能和胰岛素敏感性。
局限性
- 研究为开放标签设计,样本量较小(17例),可能影响结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve beta cell function in individuals with type 2 diabetes. It has been suggested this is due to relief of glucotoxicity, but the mechanism is unknown. The objective of the present study was to evaluate the effect of the SGLT2 inhibitor empagliflozin, compared with NPH insulin treatment, on beta cell function, and, secondarily, on insulin sensitivity. METHODS: In this open-label, randomised, cross-over study, 17 individuals with non-insulin-treated type 2 diabetes were randomised to receive 5 weeks of treatment with either empagliflozin or insulin titrated to a similar level of glycaemic control as with empagliflozin before crossing over to the other treatment. Key inclusion criteria included age ≥18 years, BMI ≥ 28 kg/m2, and a diabetes duration of more than 3 months. Treatments were preceded by a 3 week washout. Fasting and post-OGTT (5 h) metabolism were studied before and during treatments. Beta cell glucose sensitivity (bGS) was calculated as the slope of the linear relationship between the pre-hepatic insulin secretion rate and the corresponding plasma glucose value, and insulin sensitivity was calculated as glucose clearance relative to insulin concentrations. Endogenous glucose production, tissue glucose disposal and lipolysis were measured using stable isotopes. The disposition index was calculated as bGS × insulin sensitivity to assess beta cell function. Data for the present study were collected at the Department of Endocrinology, Hvidovre Hospital, Denmark. RESULTS: All participants who completed the study were included in the analyses. With equipoised glycaemic control, insulin concentrations were higher during insulin treatment than during empagliflozin treatment. bGS and insulin sensitivity were higher during empagliflozin treatment than during insulin treatment. The disposition index thus improved during empagliflozin treatment compared with insulin treatment. CONCLUSIONS/INTERPRETATION: With similar glycaemic control, insulin sensitivity was higher and beta cell function improved during empagliflozin compared with insulin treatment, possibly due to a disinhibitory effect of lower insulin concentrations. TRIAL REGISTRATION: EudraCT 2017-002101-35. FUNDING: This study was supported by Boehringer Ingelheim. Additional funding was provided by the Grosserer L.F. Foghts Fond, Charlottenlund, Denmark.
引用
- Thirumathyam R, Richter EA, van Hall G, et al. Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator. Diabetologia. 2025. PMID: 41366535. doi:10.1007/s00125-025-06616-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。